0000899243-19-030273.txt : 20191231
0000899243-19-030273.hdr.sgml : 20191231
20191231160532
ACCESSION NUMBER: 0000899243-19-030273
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191227
FILED AS OF DATE: 20191231
DATE AS OF CHANGE: 20191231
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MCCORMICK FRANK
CENTRAL INDEX KEY: 0001257809
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38959
FILM NUMBER: 191319529
MAIL ADDRESS:
STREET 1: C/O EXELIXIS INC
STREET 2: 170 HARBOR WAY
CITY: S SAN FRANCISCO
STATE: CA
ZIP: 94083-0511
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BridgeBio Pharma, Inc.
CENTRAL INDEX KEY: 0001743881
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: (650) 391-9740
MAIL ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
FORMER COMPANY:
FORMER CONFORMED NAME: BridgeBio Pharma LLC
DATE OF NAME CHANGE: 20180618
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-12-27
0
0001743881
BridgeBio Pharma, Inc.
BBIO
0001257809
MCCORMICK FRANK
C/O BRIDGEBIO PHARMA, INC.
421 KIPLING STREET
PALO ALTO
CA
94301
0
1
0
0
Chairman of Oncology
Common Stock
2019-12-27
4
S
0
25531
36.371
D
1335895
D
Common Stock
2019-12-27
4
S
0
21656
36.846
D
1314239
D
Common Stock
2019-12-27
4
S
0
3500
38.0906
D
1310739
D
Common Stock
2019-12-27
4
S
0
13705
39.273
D
1297034
D
Common Stock
2019-12-27
4
S
0
16858
40.1258
D
1280176
D
Common Stock
2019-12-27
4
S
0
883
41.3132
D
1279293
D
Common Stock
2019-12-27
4
S
0
617
42.2622
D
1278676
D
Common Stock
2019-12-27
4
S
0
100
42.93
D
1278576
D
Common Stock
2019-12-30
4
S
0
16250
35.744
D
1262426
D
Common Stock
2019-12-30
4
S
0
900
36.8574
D
1261526
D
This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 27, 2019.
Represents the weighted average sale price of the shares sold from $35.68 to $36.67 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all sales reported in footnotes 2 through 10.
Represents the weighted average sale price of the shares sold from $36.68 to $37.50 per share.
Represents the weighted average sale price of the shares sold from $37.72 to $38.71 per share.
Represents the weighted average sale price of the shares sold from $38.77 to $39.765 per share.
Represents the weighted average sale price of the shares sold from $39.77 to $40.76 per share.
Represents the weighted average sale price of the shares sold from $40.77 to $41.76 per share.
Represents the weighted average sale price of the shares sold from $41.87 to $42.84 per share.
Represents the weighted average sale price of the shares sold from $35.36 to $36.31 per share.
Represents the weighted average sale price of the shares sold from $36.5101 to $37.25 per share.
/s/ Brian Stephenson, Attorney-in-Fact
2019-12-31